Candriam S.C.A. Spring Works Therapeutics, Inc. Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

A detailed history of Candriam S.C.A. transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 845,170 shares of SWTX stock, worth $30.9 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares

845,170

Previous 522,104 61.88%

Holding current value

$30.9 Million

Previous $19.7 Million 37.69%

% of portfolio

0.16%

Previous 0.12%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$32.04 - $42.76 $10.4 Million - $13.8 Million	323,066 Added 61.88%	845,170 $27.1 Million
Q2 2024 Aug 05, 2024	BUY	$36.06 - $47.62 $11.6 Million - $15.3 Million	321,476 Added 160.23%	522,104 $19.7 Million
Q1 2024 May 03, 2024	SELL	$36.5 - $52.5 $2.74 Million - $3.94 Million	-75,000 Reduced 27.21%	200,628 $9.87 Million
Q4 2023 Feb 14, 2024	BUY	$18.94 - $37.24 $2.37 Million - $4.66 Million	125,002 Added 82.99%	275,628 $10.1 Million
Q2 2023 Aug 08, 2023	BUY	$23.15 - $32.71 $3.22 Million - $4.55 Million	139,136 Added 1210.93%	150,626 $3.95 Million
Q1 2023 May 12, 2023	SELL	$24.97 - $34.05 $3.76 Million - $5.13 Million	-150,619 Reduced 92.91%	11,490 $295,000
Q1 2022 May 13, 2022	SELL	$48.97 - $65.46 $511,589 - $683,860	-10,447 Reduced 6.05%	162,109 $9.15 Million
Q4 2021 Feb 10, 2022	BUY	$53.3 - $75.84 $1.69 Million - $2.41 Million	31,722 Added 22.52%	172,556 $10.7 Million
Q2 2021 Jul 20, 2021	BUY	$67.45 - $85.63 $334,214 - $424,296	4,955 Added 3.65%	140,834 $11.6 Million
Q1 2021 Apr 29, 2021	SELL	$65.1 - $93.59 $65 - $93	-1 Reduced -0.0%	135,879 $9.47 Million
Q4 2020 Jan 22, 2021	BUY	$48.36 - $77.92 $6.57 Million - $10.6 Million	135,880 New	135,880 $9.86 Million

Others Institutions Holding SWTX

# of Institutions

238

Shares Held

68.9M

Call Options Held

144K

Put Options Held

257K

View Full List

About SpringWorks Therapeutics, Inc.

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.28B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

More about SWTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account